       Document 0673
 DOCN  M9630673
 TI    The newer macrolides. Azithromycin and clarithromycin.
 DT    9603
 AU    Zuckerman JM; Kaye KM; Temple University School of Medicine,
       Philadelphia, Pennsylvania,; USA.
 SO    Infect Dis Clin North Am. 1995 Sep;9(3):731-45. Unique Identifier :
       AIDSLINE MED/96087611
 AB    Azithromycin and clarithromycin are structural analogues of erythromycin
       that have similar mechanisms of action. The newer macrolides have
       several distinct advantages over erythromycin, including improved oral
       bioavailability; longer half-life, allowing once or twice daily
       administration; higher tissue concentrations; and fewer gastrointestinal
       adverse effects. Clarithromycin and azithromycin also have enhanced
       antimicrobial activity. The clinical efficacy of the newer macrolides
       has been similar to erythromycin for the treatment of upper and lower
       respiratory tract and skin and soft tissue infections. New therapeutic
       roles include the use of azithromycin for C. trachomatis infections and
       the inclusion of clarithromycin or azithromycin as part of therapeutic
       regimens for disseminated MAC infections in HIV-infected patients.
       Further clinical trials are needed to determine the optimal roles for
       and uses of these new macrolides.
 DE    Antibiotics, Macrolide/*THERAPEUTIC USE  Azithromycin/ADVERSE
       EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE  Clarithromycin/ADVERSE
       EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE  Drug Resistance, Microbial  Human
       Respiratory Tract Infections/DRUG THERAPY  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

